Triple meeting 2024 – Zai Lab impresses in small cell
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
Bristol changes tack in Claudin18.2
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
Vincerx stalls again
The group reports responses with its CD123-targeting ADC, but cash is running short.
AbbVie has Met phase 3, again
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
